My Blue Dots

HOUSTON–(BUSINESS WIRE)–SynergenX Health and HerKare, two leading providers of hormone therapy and wellness services, are raising awareness about the life-changing benefits of testosterone replacement therapy (TRT) for women. Over the past decade, testosterone prescriptions have increased by almost 50% in the United States alone. Testosterone, often associated with men, is vital for women’s health, playing a key role in energy, mood, libido, and muscle maintenance. As women age, testosterone

RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck’s GARDASIL® Receives Expanded Approval for Males in China

ATLANTA–(BUSINESS WIRE)–UPS (NYSE: UPS) today announced that it has completed the acquisition of Frigo-Trans and its sister company BPL, which provide industry-leading, complex healthcare logistics solutions across Europe. The acquisitions further enhance the end-to-end capabilities available to UPS Healthcare customers, who increasingly need temperature-controlled and time-critical logistics solutions globally. Frigo-Trans’ network includes temperature-controlled warehousing ranging from cry

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutic

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights   Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sa

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, today announced Vince Stoyanov as its Chief Strategy and Development Officer. He will lead corporate development, mergers and acquisitions (M&A), and other related corporate functions, bringing both expertise and continued energy to VION at a critical moment in its expansion efforts. With more than 20 ye

BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, la plateforme d’informatique de laboratoire science-aware™, a annoncé aujourd’hui l’obtention de la certification Hébergeur de Données de Santé (HDS), une exigence obligatoire pour les organisations hébergeant des données personnelles de santé en France. L’obtention de la certification HDS souligne la conformité de Sapio Sciences aux normes strictes de sécurité, de confidentialité et de continuité opérationnelle. Cet accomplissement réaffirme l’engage

BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, the science-aware™ lab informatics platform, today announced its achievement of the Hébergeur de Données de Santé (HDS) certification, a mandatory requirement for organizations hosting personal health data in France. Achieving HDS certification underscores Sapio Sciences’ compliance with stringent security, privacy, and operational continuity standards. This accomplishment reaffirms the company’s commitment to safeguarding personal health data and adh

WUPPERTAL, Germany–(BUSINESS WIRE)–Aicuris announced today the appointment of Jacques Dumas, Ph.D., as Chief Scientific Officer (CSO), effective January 1, 2025. Dr. Dumas brings over 30 years of experience in pharmaceutical research and development (R&D), with a strong track record of advancing innovative medicines in oncology and infectious diseases from the discovery to launch. In his new role, Dr. Dumas will oversee Aicuris’ R&D efforts, ensuring alignment with the company’s strat